# Italy Microbiome Sequencing Services Market > Italy Microbiome Sequencing Services Market Research Report: Size, Share, Trend Analysis By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) andBy Applications (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 12.98% - **2024:** $ 52.08 Million - **2025:** $ 58.84 Million - **2035:** $ 199.35 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HC/52150-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/italy-microbiome-sequencing-services-market-53912 --- ## Market Summary ## **Italy Microbiome Sequencing Services Market Overview****:** As per MRFR analysis, the Italy Microbiome Sequencing Services Market Size was estimated at 56.78 (USD Million) in 2023. The Italy Microbiome Sequencing Services Market Industry is expected to grow from 62.4(USD Million) in 2024 to 340.2 (USD Million) by 2035. The Italy Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 16.67% during the forecast period (2025 - 2035). ### **Key Italy Microbiome Sequencing Services Market Trends Highlighted** A variety of factors are driving the substantial growth of the Italy Microbiome Sequencing Services Market. The demand for sequencing services is being driven by the growing comprehension of the human microbiome and its influence on health. The Italian biotechnology industry is currently focused on the development of innovative solutions that appeal to personalized medicine and precise healthcare, as research continues to establish connections between the microbiome and a variety of diseases. The increasing demand for personalized nutrition and preventive health is resulting in an increasing number of partnerships between private enterprises and research institutions in Italy.  In areas such as infectious diseases, metabolic disorders, and gastrointestinal health, opportunities are arising that enable Italian firms to personalize their service offerings. Additionally, collaborations between agricultural enterprises and academia are being prompted by the agricultural sector's recognition of the role of microbiomes in improving crop health and productivity.  In recent years, there has been an increase in government funding and initiatives that are designed to promote microbiome research and innovation. The Ministry of University and Research of Italy is promoting the development of microbiome sequencing programs, which are fostering the expansion of academic and clinical research in the country. Furthermore, the rapid and precise analysis of microbial communities is being facilitated by the emergence of advanced sequencing technologies.  Italian researchers are influencing practices in a variety of disciplines, such as medicine and agriculture, as they publish more studies on the microbiome.Italy is emerging as a burgeoning center for microbiome sequencing services, which will ultimately result in enhanced health outcomes and agricultural productivity as a result of the changing landscape of microbiome understanding. The microbiome sequencing services market in Italy is poised for a promising future as a result of the increasing industry investments and academic expertise. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **Italy Microbiome Sequencing Services Market Drivers** ### **Rising Prevalence of Gastrointestinal Disorders** The increasing incidence of gastrointestinal disorders in Italy significantly impacts the Italy [Microbiome Sequencing Services Market](../../../reports/microbiome-sequencing-services-market-7532). Studies indicate that approximately 25% of the Italian population experiences some form of gastrointestinal discomfort, which is often linked to imbalances in gut microbiota. Organizations like the Italian Society of Gastroenterology are actively promoting awareness and treatments that integrate microbiome research, enhancing the demand for sequencing services to understand these disorders better.The Italian government is also supporting research initiatives that focus on gut health, thereby driving the market forward. ### **Advancements in Personalized Medicine** The development of personalized medicine is becoming a transformative factor in the Italy Microbiome Sequencing Services Market. With an emphasis on tailored treatments, there has been a steady rise in Research and Development activities in Italy's biotechnology sector. In 2022, investments in biotechnology in Italy reached over USD 2 billion, underscoring the sector's commitment to integrating microbiome data into healthcare strategies. Companies like Menarini and Dompé Farmaceutici are leading efforts to incorporate microbiome sequencing to optimize patient treatment plans, which is expected to propel market growth. ### **Increasing Investment in Microbiome Research** Investment in microbiome research in Italy is surging, driven by both government initiatives and the private sector. The Italian Ministry of Health allocated approximately USD 500 million in 2023 to support innovative research aimed at understanding the implications of microbiome variations for health and disease. This influx of funding enables research institutions and universities, such as the University of Milan, to enhance their microbiome sequencing capabilities, facilitating advancements in the Italy Microbiome Sequencing Services Market Industry and promoting local innovation. ### **Growing Awareness of Gut-Brain Axis** The connection between the gut microbiome and mental health is gaining traction in Italy, significantly influencing the Italy Microbiome Sequencing Services Market Industry. Research indicates that around 15% of Italians experience mental health issues, and studies suggest that gut microbiota can affect mood and cognitive function. Institutions like the Italian Institute of Health are encouraging interdisciplinary studies on the gut-brain axis, which fosters a greater understanding of how microbiome sequencing can be utilized.The growing consumer interest in holistic health approaches drives demand for microbiome analysis, thus supporting market expansion. ## **Italy Microbiome Sequencing Services Market Segment Insights****:** ### **Microbiome Sequencing Services Market Technology Insights** The Technology segment of the Italy Microbiome Sequencing Services Market represents an increasingly crucial aspect of the healthcare and biotechnology landscape. With a strong focus on advancing methodologies, the various techniques are essential for extracting invaluable microbiome data, ultimately improving patient outcomes and advancing scientific research. Sequencing by Litigation (SBL) offers unique capabilities in analyzing complex microbial ecosystems, enabling more detailed and accurate profiles of microbiomes in various environments, which is particularly relevant as Italy continues to promote sustainable healthcare solutions.Sequencing by Synthesis (SBS) stands out for its high throughput and cost-effectiveness in DNA analysis, making it pivotal in both clinical settings and academic research, propelling initiatives that align with Italy's objectives in enhancing diagnostics and personalized medicine.  Short Gun Sequencing serves as an effective tool, allowing researchers to explore genomes comprehensively, which supports Italy's aspirations in genetic research and targeted therapies, facilitating groundbreaking discoveries in unpredictable landscapes of health and disease.Targeted Gene Sequencing focuses on specific genes of interest, offering a targeted approach that aligns seamlessly with Italy's ongoing endeavors in precision medicine and rare disease research, as this technique can help identify genetic predispositions effectively. RNA Sequencing, with its ability to analyze transcriptomic data, plays a vital role in understanding gene expression profiles in various health conditions.  It fosters innovations that contribute to Italy's striving for advancements in genomics and treatment methods. Lastly, the category of Others encompasses emerging and specialized technologies that are continually evolving to meet the changing demands of the sector, ensuring that Italy remains at the forefront of microbiome research and application.Collectively, the diverse techniques in this Technology segment of the Italy Microbiome Sequencing Services Market are not only significant for enhancing scientific understanding but also for positioning Italy as a leader in microbiome-related healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Microbiome Sequencing Services Market Application Insights** The Italy Microbiome Sequencing Services Market, particularly in the Application segment, presents a diverse landscape that addresses various health challenges. Key areas within this segment include Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, and Others. Gastrointestinal Diseases have gained attention due to their increasing prevalence in Italy, with microbiome research revealing significant links between gut health and overall wellness. Infectious Diseases play a critical role as rising concerns around antimicrobial resistance prompt deeper investigations into microbial profiles, assisting in targeted treatment approaches. Central Nervous System (CNS) Diseases are also noteworthy, as innovative studies illustrate the potential impact of the microbiome on neurological and psychiatric conditions. Oncology is particularly significant, as research increasingly supports the use of microbiome analysis for personalized cancer therapies and treatment responses. Lastly, the Others category encompasses emerging applications, reflecting the growing interdisciplinary integration of microbiome insights across various medical fields. The interplay of these applications supports the overall growth and transformation of the Italy Microbiome Sequencing Services Market, underscoring the importance of microbiome research in enhancing health outcomes in the region. ## **Italy Microbiome Sequencing Services Market Key Players and Competitive Insights****:** The Italy Microbiome Sequencing Services Market showcases a dynamic landscape characterized by a mix of established players and emerging companies competing in the biotechnology sector. The market is fueled by a surge in demand for personalized medicine, as well as an increased focus on gut health and its connection to overall wellness. Advancements influence the competitive environment in sequencing technologies which have made microbiome analysis more accessible and affordable. Furthermore, regulatory approvals and collaborations with academic institutions and healthcare providers are driving innovation and expanding the market presence of key players. Companies are continuously investing in research and development to refine their service offerings and enhance data analysis capabilities, which positions them favorably amidst intensifying competition.  ZyGenome stands out in the Italian Microbiome Sequencing Services Market due to its strong emphasis on delivering comprehensive microbiome profiling solutions tailored for various applications, including health, nutrition, and environmental studies. The company leverages advanced sequencing technologies to offer high-resolution insights into individual microbiomes, catering to healthcare professionals and researchers who seek personalized data. ZyGenome's strategic collaborations with local healthcare providers and universities have bolstered its presence in Italy, allowing the company to solidify its reputation as a trusted player in the market.  Additionally, ZyGenome highlights its commitment to quality and service excellence, which has garnered strong customer loyalty and confidence in its offerings, further enhancing its competitive edge in the region.CosmosID is another notable entity in the Italy Microbiome Sequencing Services Market, recognized for its cutting-edge bioinformatics platform designed specifically for microbiome analysis. The company provides a portfolio of services that include metagenomic sequencing, strain-level identification, and multi-omic integration, catering to academic research institutions and clinical laboratories. CosmosID's strength lies in its innovative approach to data interpretation, providing actionable insights for researchers investigating complex microbial ecosystems.  The company has established a robust market presence through strategic partnerships with research organizations and healthcare entities, which facilitates access to a broader customer base. Furthermore, CosmosID’s commitment to improving health outcomes through microbiome research is reflected in its ongoing collaborations and acquisitions aimed at strengthening its technological capabilities in Italy, allowing it to remain competitive while addressing the growing demand for microbiome analytics in the region. ### **Key Companies in the Italy Microbiome Sequencing Services Market Include:** - ZyGenome - CosmosID - BaseClear - Nexgene - Advanced Microbial Sequencing - Qiagen - Ginkgo BioWorks - Thermo Fisher Scientific - Illumina - Bioservice - Novogene - Genomatix - Microbial Genomics ## **Italy Microbiome Sequencing Services Market Industry Developments** Recent developments in the Italy Microbiome Sequencing Services Market show a growing interest in the application of microbiome data for various sectors, including healthcare, agriculture, and environmental monitoring. Companies such as Ginkgo BioWorks and Illumina are actively expanding their services to include customized microbiome sequencing solutions, catering to unique client needs. In terms of market dynamics, Qiagen and Thermo Fisher Scientific have seen an increase in their market valuation, fueled by rising investments in genomic research and personalized medicine across Italy.  Notably, in March 2023, BaseClear launched a new microbiome analysis service that enhances the overall capabilities within the country. Additionally, Advanced Microbial Sequencing announced a strategic partnership with local universities to drive microbiome research, reflecting growing academic interest. Over the past two years, the sector has witnessed increasing collaborations, with several players exploring joint ventures to streamline their offerings.  There have been reports of potential mergers, with rumors speculating on possible strategic consolidations involving ZyGenome and CosmosID, but no confirmed announcements have surfaced. The Italian government has also increased funding initiatives to promote research and development in biotechnology, signaling robust growth prospects for microbiome sequencing services. ## **Italy Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Increased Research Funding The microbiome sequencing-services market in Italy is benefiting from increased funding for microbiome research. Government and private institutions are allocating substantial resources to study the human microbiome and its implications for health and disease. In recent years, funding for microbiome-related research projects has seen a notable increase, with investments reaching over €50 million annually. This financial support is fostering innovation and development in sequencing technologies, which in turn enhances the capabilities of service providers in the microbiome sequencing-services market. As research progresses, new applications and insights are likely to emerge, further stimulating demand for sequencing services. The influx of funding is expected to bolster collaborations between academic institutions and industry players, creating a robust ecosystem for microbiome research and services. ### Advancements in Bioinformatics The microbiome sequencing-services market is experiencing growth due to advancements in bioinformatics technologies. These innovations are enhancing the ability to analyze complex microbiome data, making it more accessible and interpretable for both researchers and consumers. In Italy, the development of sophisticated bioinformatics tools is enabling service providers to offer more accurate and comprehensive microbiome analyses. This is particularly important as the volume of sequencing data continues to increase. The integration of artificial intelligence and machine learning in data analysis is expected to improve the efficiency and effectiveness of microbiome research. As bioinformatics capabilities expand, the microbiome sequencing-services market is likely to see a surge in demand for advanced analytical services, which could lead to a market growth rate of around 12% over the next few years. ### Growing Interest in Gut Health The increasing awareness of gut health among the Italian population is driving the microbiome sequencing-services market. Consumers are becoming more informed about the role of gut microbiota in overall health, leading to a surge in demand for microbiome analysis. This trend is reflected in the rising sales of probiotics and dietary supplements, which are often marketed based on their microbiome benefits. In Italy, the market for probiotics is projected to reach approximately €300 million by 2026, indicating a strong consumer interest in gut health. As individuals seek personalized insights into their microbiomes, the demand for sequencing services is likely to grow, further propelling the microbiome sequencing-services market. This growing interest in gut health is expected to create new opportunities for service providers in the sector. ### Rising Prevalence of Chronic Diseases The increasing prevalence of chronic diseases in Italy is a significant driver for the microbiome sequencing-services market. Conditions such as obesity, diabetes, and inflammatory bowel diseases are becoming more common, prompting healthcare professionals to explore the role of the microbiome in disease management. Studies suggest that alterations in gut microbiota may contribute to the onset and progression of these conditions. As a result, there is a growing interest among healthcare providers in utilizing microbiome sequencing to develop personalized treatment plans. The Italian healthcare system is increasingly recognizing the potential of microbiome analysis in preventive care and disease management, which could lead to a market growth rate of approximately 15% annually in the coming years. This trend indicates a shift towards integrating microbiome insights into clinical practice. ### Consumer Demand for Nutritional Insights There is a notable shift in consumer behavior in Italy towards seeking nutritional insights tailored to individual microbiomes. As people become more health-conscious, they are increasingly interested in understanding how their unique microbiota influences their dietary needs. This trend is driving the microbiome sequencing-services market, as individuals seek personalized dietary recommendations based on their microbiome profiles. The rise of health and wellness apps that incorporate microbiome data is further fueling this demand. It is estimated that the market for personalized nutrition services could reach €1 billion by 2027 in Italy, highlighting the potential for growth in the microbiome sequencing-services market. This consumer-driven demand for tailored nutritional insights is likely to encourage service providers to innovate and expand their offerings. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) in Italy is projected to grow at a 12.98% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations. **New opportunities:** - Development of targeted microbiome therapies for chronic diseases - Expansion of subscription-based microbiome analysis services - Partnerships with healthcare providers for integrated microbiome solutions By 2035, the market is expected to be robust, driven by innovation and strategic partnerships. ## Segment Insights ### By Technology: Sequencing by Synthesis (Largest) vs. RNA Sequencing (Fastest-Growing) In the Italy microbiome sequencing-services market, Sequencing by Synthesis (SBS) has emerged as the largest segment, owing to its established methodologies and comprehensive applications across various research fields. Other segments like Sequencing by Litigation (SBL) and Short Gun Sequencing have also made their mark, but none have surpassed the widespread adoption and preference for SBS, which continues to dominate market share distribution. On the other hand, RNA Sequencing is recognized as the fastest-growing segment, fueled by the increasing interest in transcriptomics and personalized medicine. The advancements in technology and reduction in costs have driven this growth, making RNA Sequencing a preferred choice for researchers aiming to explore gene expression and its implications in various biological processes, thus highlighting the evolving landscape of sequencing technologies. Technology: Sequencing by Synthesis (Dominant) vs. RNA Sequencing (Emerging) Sequencing by Synthesis (SBS) stands at the forefront of the Italy microbiome sequencing-services market, reflecting a dominant position due to its reliability and versatility in applications. It facilitates high-throughput sequencing with accurate results, catering to a broad range of scientific inquiries. In contrast, RNA Sequencing is an emerging player gaining traction, particularly in the context of studying gene activity. This technology is rapidly expanding, propelled by innovations that enhance data interpretation and the significance of RNA profiles in understanding health and disease. The juxtaposition of these two methods highlights the dynamic nature of sequencing technologies in advancing microbiome research. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) The Italy microbiome sequencing-services market shows a significant distribution of market share among various application segments. Gastrointestinal diseases hold the largest share, as this field has seen a surge in demand for microbiome analysis to understand the complexities of gut health. Infectious diseases follow closely, with a noticeable contribution from CNS diseases and oncology, reflecting the escalating focus on personalized medicine and targeted therapies. In recent years, the oncology segment has been identified as the fastest-growing, driven by increasing investments in cancer research and the development of microbiome-centric therapies. As healthcare providers recognize the pivotal role of the microbiome in disease progression and treatment response, the integration of sequencing services in oncology is expected to accelerate. This trend is facilitated by advancements in sequencing technology and rising awareness among patients and clinicians. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal diseases represent a dominant force in the Italy microbiome sequencing-services market, characterized by a strong demand for diagnostic and therapeutic solutions. The understanding of the gut microbiome's role in health and disease has catalyzed innovations in sequencing technologies, enabling more accurate and efficient analysis. This dominance is supported by an increasing prevalence of gastrointestinal disorders, coupled with the growing emphasis on preventative healthcare. On the other hand, oncology is emerging rapidly, with significant interest in how microbiome variations may influence cancer development and treatment efficacy. The oncology segment's growth is spurred by ongoing research into microbiome interactions and their implications in personalized treatment plans, promising substantial advancements in the field. ## Competitive Benchmarking The microbiome sequencing services market in Italy is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in genomic technologies. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their technological expertise and extensive product portfolios to capture market share. Illumina (US) focuses on innovation in sequencing technologies, while Thermo Fisher Scientific (US) emphasizes comprehensive solutions that integrate sample preparation and analysis. Qiagen (DE) is strategically positioned through its robust bioinformatics capabilities, which enhance data interpretation and application in clinical settings. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and customer-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Illumina (US) and Thermo Fisher Scientific (US) suggests a trend towards consolidation, as these firms seek to expand their market presence through strategic partnerships and acquisitions. In October 2025, Illumina (US) announced a collaboration with a leading Italian research institution to develop a novel microbiome analysis platform. This partnership is expected to enhance the company’s capabilities in providing tailored microbiome solutions, thereby solidifying its position in the Italian market. The strategic importance of this collaboration lies in its potential to accelerate innovation and improve customer access to cutting-edge sequencing technologies. In September 2025, Thermo Fisher Scientific (US) launched a new line of microbiome sequencing kits specifically designed for clinical applications. This move is indicative of the company’s commitment to expanding its product offerings in the healthcare sector, which is increasingly focused on personalized medicine. The introduction of these kits is likely to enhance the company’s competitive edge by addressing the growing demand for precise and efficient microbiome analysis in clinical settings. In August 2025, Qiagen (DE) expanded its bioinformatics platform to include advanced analytics for microbiome data interpretation. This enhancement is crucial as it allows researchers and clinicians to derive actionable insights from complex microbiome data, thereby improving patient outcomes. The strategic significance of this development lies in its ability to position Qiagen (DE) as a leader in the integration of bioinformatics with microbiome sequencing, catering to the evolving needs of the market. As of November 2025, current trends in the microbiome sequencing-services market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing service offerings. Looking ahead, it is anticipated that competitive differentiation will increasingly pivot from price-based strategies to a focus on technological innovation, reliability in supply chains, and the ability to deliver comprehensive, data-driven solutions. ## Recent News & Developments Recent developments in the Italy Microbiome Sequencing Services Market show a growing interest in the application of microbiome data for various sectors, including healthcare, agriculture, and environmental monitoring. Companies such as Ginkgo BioWorks and Illumina are actively expanding their services to include customized microbiome sequencing solutions, catering to unique client needs. In terms of market dynamics, Qiagen and Thermo Fisher Scientific have seen an increase in their market valuation, fueled by rising investments in genomic research and personalized medicine across Italy.  Notably, in March 2023, BaseClear launched a new microbiome analysis service that enhances the overall capabilities within the country. Additionally, Advanced Microbial Sequencing announced a strategic partnership with local universities to drive microbiome research, reflecting growing academic interest. Over the past two years, the sector has witnessed increasing collaborations, with several players exploring joint ventures to streamline their offerings.  There have been reports of potential mergers, with rumors speculating on possible strategic consolidations involving ZyGenome and CosmosID, but no confirmed announcements have surfaced. The Italian government has also increased funding initiatives to promote research and development in biotechnology, signaling robust growth prospects for microbiome sequencing services. ## Report Scope | MARKET SIZE 2024 | 52.08(USD Million) | | --- | --- | | MARKET SIZE 2025 | 58.84(USD Million) | | MARKET SIZE 2035 | 199.35(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.98% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in microbiome sequencing-services, influenced by regulatory advancements and technological innovations. | | Countries Covered | Italy | ## Frequently Asked Questions **Q: What was the market valuation of the microbiome sequencing-services market in 2024?** A: The market valuation was $52.08 Million in 2024. **Q: What is the projected market valuation for the microbiome sequencing-services market by 2035?** A: The projected valuation for 2035 is $199.35 Million. **Q: What is the expected CAGR for the microbiome sequencing-services market during the forecast period 2025 - 2035?** A: The expected CAGR is 12.98% during the forecast period 2025 - 2035. **Q: Which technology segment had the highest valuation in 2024?** A: The Sequencing by Synthesis (SBS) segment had the highest valuation at $15.62 Million in 2024. **Q: What is the projected valuation for the Sequencing by Litigation (SBL) segment by 2035?** A: The projected valuation for the Sequencing by Litigation (SBL) segment is $20.0 Million by 2035. **Q: Which application segment is expected to grow the most by 2035?** A: The Oncology application segment is expected to grow the most, with a projected valuation of $50.0 Million by 2035. **Q: What was the valuation of the Gastrointestinal Diseases application segment in 2024?** A: The valuation of the Gastrointestinal Diseases application segment was $10.42 Million in 2024. **Q: Who are the key players in the microbiome sequencing-services market?** A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID. **Q: What is the projected valuation for the RNA Sequencing segment by 2035?** A: The projected valuation for the RNA Sequencing segment is $25.0 Million by 2035. **Q: What was the valuation of the Others segment in the Technology category in 2024?** A: The Others segment in the Technology category had a valuation of $5.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/italy-microbiome-sequencing-services-market-53912*